

Point of Care Coagulation Testing: World Market 2013-2023

<https://marketpublishers.com/r/P3A60943C21EN.html>

Date: April 2013

Pages: 106

Price: US\$ 2,635.00 (Single User License)

ID: P3A60943C21EN

Abstracts

In 2011, the global point of care diagnostics market was worth \$13.8bn, with high single-digit growth from the year before. Despite being a vast and mature market, there are number of sectors likely to experience fast growth during the next 10 years. Much of this growth is linked to the prevalence of a number of diseases worldwide, as well as an aging population. The preference for at home testing and its convenience will continue to drive the point of care diagnostics market.

The point of care coagulation market is one of the largest sectors in the global point of care industry. In 2011, the global POC coagulation testing market (including the sales of kits and instruments) was valued at \$1.0bn. Total sales in this market are predicted to reach \$1.8bn in 2017. PT/INR testing was the largest segment in the POC coagulation testing market with sales of \$0.6bn in 2011.

For the past several years, four companies - Roche, International Technidyne Corporation (ITC), Abbott, and Alere - have dominated the POC PT/INR testing market. The devices currently available in the market are able to meet demand. However, there is need for improvement in technology to attract more physicians and patients to use this testing. Most of the testing for patients on anticoagulant warfarin is currently conducted in laboratories. Such patients need regular monitoring. The use of POC tests can help save a lot of time and money spent on unwanted complications arising from the use of the drug without monitoring.

The primary driver for growth will be the increasing use of anticoagulant therapy and higher adoption of self-testing kits for use at home. Anticoagulant drugs are commonly used for the treatment of thrombosis and associated disorders, including stroke, myocardial infarction and pulmonary embolism. The global epidemic of heart attack and

stroke is predicted to continue and indeed worsen, from 2011 to 2023. However, market growth will slow down beyond 2017, with the launch of new oral anticoagulants in the market to replace warfarin.

Point of Care Coagulation Testing: World Market 2013-2023 provides an in-depth analysis of this segment. The report uses a wealth of research tools - including market forecasting, qualitative analyses, probing interviews with industry experts, literature searches and use of commercial databases. The report is packed with original data in tables, charts and other formats.

Why you should buy Point of Care Coagulation Testing: World Market 2013-2023

In this report, you will receive the following benefits:

You will receive a comprehensive analysis of prospects in the point of care coagulation testing market as a whole from 2011 to 2023, including predicted market sizes, growth rates and other metrics for leading sectors

You will receive an overall forecast for the point of care market and point of care coagulation testing market from 2012 to 2023, as well as that for the PT/INR market, with discussions and other supporting information

You will receive an overall forecast for the anticoagulant drug market from 2012 to 2023, with comprehensive discussions and other supporting information

You will discover revenue forecasts to 2023 for leading national markets (US, Europe, and Rest of the World), seeing growth trends

You will receive analysis of leading companies in the point of care coagulation testing market

You will find out where the market is heading - both technologically and commercially - from 2012 onwards

You will discover the drivers, restraints, competition and opportunities influencing the point of care coagulation testing market

You will identify where new opportunities lie in these sectors, with commercial opportunities and challenges discussed

You will view opinions from our industry survey, receiving full interview transcripts.

You can order this report today

Order our report now to gain industry and market analysis for the point of care coagulation testing market.

Our report is for everybody interested in market analysis, product development, sales and marketing for point of care coagulation devices. You will find predictions and answers. Don't miss out - please order our report now.

Contents

1. EXECUTIVE SUMMARY

- 1.1 The Point of Care (POC) Coagulation Testing Market Review
- 1.2 Aims, SCoPe and Format of the Report
 - 1.2.1 Chapter Outlines
- 1.3 ResearCh and Analysis Methods

2. INTRODUCTION TO IN-VITRO DIAGNOSTICS AND POC DIAGNOSTICS

- 2.1 What are In Vitro DiagnostiC (IVD) Tests?
- 2.2 Classifying IVD: EDMA ClassifiCation
 - 2.2.1 CliniCal Chemistry
 - 2.2.2 ImmunoChemistry
 - 2.2.3 Haematology
 - 2.2.4 MiCrobiology
 - 2.2.5 GenetiC Testing
- 2.3 Point of Care (POC) DiagnostiCs
 - 2.3.1 Advantages and Disadvantages of POC DiagnostiCs
- 2.4 Regulation of the IVD and POC Market
 - 2.4.1 FDA ClassifiCations
 - 2.4.2 FDA and CLIA Regulation of IVD and POC Tests
 - 2.4.3 Regulation of IVD/POC DiagnostiCs in the EU

3. THE POINT OF CARE DIAGNOSTICS MARKET, 2011-2023

- 3.1 Point of Care DiagnostiCs Market, 2011
- 3.2 Blood GluCose Testing is the Largest Contributor to the POC Market Sales
- 3.3 Self Testing - Largest Segment in the POC Market by the Point of Delivery, 2011
- 3.4 Point of Care DiagnostiCs Market ForeCast, 2012-2017
- 3.5 Point of Care DiagnostiCs Market ForeCast, 2017-2023

4. POC COAGULATION TESTING MARKET, 2011-2023

- 4.1 The POC Coagulation Testing Market in 2011
 - 4.1.1 PT/INR Monitoring is the Largest Segment in the POC Coagulation Testing Market
 - 4.1.2 RoChe Dominates the POC Coagulation Testing Market with CoaguChek XS

System

- 4.2 Products Available in the POC Coagulation Testing Market, 2013
- 4.3 POC Coagulation Testing Will Witness Strong Growth to 2017
- 4.4 POC Coagulation Testing Market Forecast, 2017-2023
- 4.5 Drivers for Growth

5. THE PT/INR TESTING MARKET, 2011-2023

- 5.1 Patient Self Testing is the Smallest, But Fastest Growing Segment
- 5.2 Test Strips Generate 85% of the Sales in the PT/INR POC Testing Market
- 5.3 PT/INR Testing Market Forecast, 2012-2023

6. ANTICOAGULANT DRUGS MARKET, 2011-2023

- 6.1 AntiCoagulants
 - 6.1.1 Heparins
 - 6.1.2 Vitamin K Antagonists
 - 6.1.3 Direct Thrombin Inhibitors
 - 6.1.4 Direct Factor Xa Inhibitors
- 6.2 The AntiCoagulants Market in 2011
- 6.3 AntiCoagulants Market Forecast, 2012-2023
- 6.4 Vitamin K Antagonists
 - 6.4.1 The Vitamin K Antagonists Market in 2011
 - 6.4.2 Vitamin K Antagonists: Market Sector Forecast, 2012-2023

7. LEADING NATIONAL MARKETS FOR POC PT/INR TESTING, 2011-2023

- 7.1 The US is the Largest Market for POC PT/INR Testing
- 7.2 Coagulation Self-Monitoring: Reimbursement Status
- 7.3 The US Market
- 7.4 The European Market
 - 7.4.1 Germany
 - 7.4.2 The UK
 - 7.4.3 France
 - 7.4.4 Other European Countries
- 7.5 Rest of the World Markets
 - 7.5.1 Japanese Market
 - 7.5.2 Indian Market

8. LEADING COMPANIES IN THE POC PT/INR TESTING MARKET

8.1 Four Companies Dominate the POC PT/INR Testing Market

8.2 Company Profiles

8.2.1 RoChe

8.2.1.1 Global PresenCe

8.2.1.2 Sales and ReCent PerformanCe Analysis

8.2.1.3 RoChe DiagnostiCs

8.2.1.4 Growing Portfolio of Coagulation Testing ProduCts

8.2.1.5 ReCent M&A ACTivity and StrategiC Collaborations

8.2.2 Abbott Laboratories

8.2.2.1 Sales and ReCent PerformanCe Analysis

8.2.2.2 Abbott: DiagnostiCs Segment

8.2.2.3 Point of Care DiagnostiCs ProduCts

8.2.2.4 Abbott IVD Segment: Strengths & Challenges

8.2.2.5 Abbott DiagnostiCs HistoriCal Revenues, 2009-2011

8.2.2.6 ReCent M&A ACTivity and StrategiC Collaborations

8.2.2.6.1 Collaboration with GSK

8.2.2.6.2 Collaboration with MerCk

8.2.2.6.3 ACquisition of STARLIMS TeChnologies

8.2.2.6.4 ACquisition of Ibis BiosCienCes

8.2.3 International TeChnidyne Corporation (ITC)

8.2.3.1 Overview

8.2.3.2 ProduCts

8.2.3.3 Blood Coagulation Monitor DeviCes

9. PRODUCTS IN THE PIPELINE

9.1 POC Coagulation Test Systems in Development

9.1.1 Portable Coagulation Monitor, Entegriion

9.1.2 Blood Coagulation Monitor, Bio-AMD

9.1.3 Siemens-Universal Biosensors Collaboration

10. SWOT ANALYSIS OF THE POC COAGULATION TESTING MARKET, 2013-2023

10.1 Strengths and Weaknesses of the SeCtor

10.1.1 ThrombotiC Diseases: Management Rather Than Cure

10.1.2 Better Patient and Disease Management

10.1.3 Warfarin Has Been the AntiCoagulant of ChoiCe for More Than 50 Years

- 10.1.4 Availability of Several POC Devices
- 10.1.5 Availability of International Guidelines for Self-Monitoring
- 10.1.6 The Cost of POC Tests
- 10.1.7 Educating the End-Users
- 10.2 Opportunities and Threats
 - 10.2.1 Consistent Technological Developments
 - 10.2.2 Rising Disease Prevalence
 - 10.2.3 Launch of New Class of Anticoagulants
 - 10.2.4 Expansion into Developing National Markets and Lifestyle Diseases Will Drive the Market
 - 10.2.5 High-Entry Barriers in the POC Blood Coagulation Testing Market
 - 10.2.6 Medical Device Excise Tax: A Threat to the OEMs

11. EXPERT OPINION

- 11.1 Interview with Dr Frank Peacock, Professor, Associate Chair and Research Director, Baylor College of Medicine, Houston, Texas
 - 11.1.1 Warfarin vs Novel Oral Anticoagulants
 - 11.1.2 The Unmet Needs of the Market
 - 11.1.3 The R&D Pipeline
 - 11.1.4 Key Market Drivers and Restraints
- 11.2 Interview with Dr Jonathan L. Halperin, Professor of Medicine, Director of Clinical Cardiology Services, Zena and Michael A. Wiener Cardiovascular Institute, The Mount Sinai Medical Center, New York
 - 11.2.1 Unmet Needs
 - 11.2.2 New Findings
 - 11.2.3 Warfarin Replacement
 - 11.2.4 Areas Demanding Attention
 - 11.2.5 Key Market Restraints

12. CONCLUSIONS

- 12.1 Overview of Point of Care Coagulation Testing
- 12.2 Commercial Drivers for the Adoption of POC Coagulation Tests
- 12.3 Commercial Restraints in the POC Coagulation Testing Market
- 12.4 Growth of POC Coagulation Testing Market from 2013 to 2023
- 12.5 Future Outlook and Concluding Remarks

List Of Tables

LIST OF TABLES

- Table 2.1 Advantages and Disadvantages of POC DiagnostiCs
- Table 3.1 POC Market by Leading Segments, Sales (\$bn) and Market Share (%), 2011
- Table 3.2 Self Testing & Professional Testing in the POC Market (\$bn), 2011
- Table 3.3 World POC DiagnostiCs Market ForeCast (\$bn), 2011-2017
- Table 3.4 World POC DiagnostiCs Market ForeCast (\$bn), 2017-2023
- Table 4.1 Global POC Coagulation Testing Market (\$m) by Marker, 2011
- Table 4.2 Global POC Coagulation Testing Market (\$m) by Leading Companies, 2011
- Table 4.3 List of Some ProduCts in the POC Coagulation Testing Market, 2013
- Table 4.4 The POC Coagulation Testing Market ForeCast (\$bn), 2011-2017
- Table 4.5 The POC Coagulation Testing Market ForeCast (\$bn), 2017-2023
- Table 5.1 PT/INR POC Testing Market (\$m) by Point of Use, 2011
- Table 5.2 The PriCe of Some POC PT/INR Testing Systems, 2012
- Table 5.3 PT/INR POC Testing Market (\$m) by Components, 2011
- Table 5.4 The PT/INR Testing Market ForeCast (\$m), 2011-2017
- Table 5.5 The PT/INR Testing Market ForeCast (\$m), 2017-2023
- Table 6.1 AntiCoagulant Drug Market: Revenues (\$m) by Class, 2011
- Table 6.2 AntiCoagulant Classes: Revenue ForeCasts (\$m), 2011-2017
- Table 6.3 AntiCoagulant Classes: Revenue ForeCasts (\$m), 2018-2023
- Table 6.4 Vitamin K Antagonists: Market SeCtor ForeCast (\$m), 2011-2023
- Table 6.5 The Vitamin K Antagonist Market: Drivers and Restraints, 2013-2023
- Table 7.1 PT/INR POC Testing Market (\$m) by Region, 2011
- Table 7.2 Leading National PT/INR Testing Market ForeCast (\$m), 2011-2023
- Table 7.3 Reimbursement for Coagulation Self-Monitoring In the US and Some European Countries, 2011
- Table 7.4 The US PT/INR Testing Market ForeCast (\$m), 2011-2023
- Table 7.5 The European PT/INR Testing Market ForeCast (\$m), 2011-2023
- Table 7.6 Rest of the World PT/INR Testing Market ForeCast (\$m), 2011-2023
- Table 8.1 POC PT/INR Testing Market (\$m) by Companies, 2011
- Table 8.2 RoChe: Key FaCts, 2013
- Table 8.3 RoChe: Revenue (\$bn) and Revenue Shares (%) by SeCtor, 2011
- Table 8.4 RoChe DiagnostiCs: Revenue (\$bn) and Revenue Shares (%), by Region, 2011
- Table 8.5 RoChe DiagnostiCs: Revenue (\$bn) and Revenue Shares (%) by SeCtor, 2011
- Table 8.6 Abbott: Key FaCts, 2013

Table 8.7 Abbott: Net Sales (\$bn) & Net Sales Shares (%), By Business Segment, 2011

Table 8.8 Abbott: Net Sales (\$bn) and Net Sales Shares (%), by Geographical Region, 2011

Table 8.9 Abbott Diagnostics: Net Sales (\$bn) and Net Sales Shares by Sub-Segment, 2011

Table 8.10 Abbott: Diagnostics Net Sales (\$bn), 2009-2011

Table 9.1 List of Some POC Coagulation Tests Under Development, 2011

Table 10.1 SWOT Analysis of the POC Coagulation Testing Market

About

In 2011, the global point of care diagnostics market was worth \$13.8bn, with high single-digit growth from the year before. Despite being a vast and mature market, there are number of sectors likely to experience fast growth during the next 10 years. Much of this growth is linked to the prevalence of a number of diseases worldwide, as well as an aging population. The preference for at home testing and its convenience will continue to drive the point of care diagnostics market.

The point of care coagulation market is one of the largest sectors in the global point of care industry. In 2011, the global POC coagulation testing market (including the sales of kits and instruments) was valued at \$1.0bn. Total sales in this market are predicted to reach \$1.8bn in 2017. PT/INR testing was the largest segment in the POC coagulation testing market with sales of \$0.6bn in 2011.

For the past several years, four companies - Roche, International Technidyne Corporation (ITC), Abbott, and Alere - have dominated the POC PT/INR testing market. The devices currently available in the market are able to meet demand. However, there is need for improvement in technology to attract more physicians and patients to use this testing. Most of the testing for patients on anticoagulant warfarin is currently conducted in laboratories. Such patients need regular monitoring. The use of POC tests can help save a lot of time and money spent on unwanted complications arising from the use of the drug without monitoring.

The primary driver for growth will be the increasing use of anticoagulant therapy and higher adoption of self-testing kits for use at home. Anticoagulant drugs are commonly used for the treatment of thrombosis and associated disorders, including stroke, myocardial infarction and pulmonary embolism. The global epidemic of heart attack and stroke is predicted to continue and indeed worsen, from 2011 to 2023. However, market growth will slow down beyond 2017, with the launch of new oral anticoagulants in the market to replace warfarin.

“Point of Care Coagulation Testing: World Market 2013-2023” provides an in-depth analysis of this segment. The report uses a wealth of research tools - including market forecasting, qualitative analyses, probing interviews with industry experts, literature searches and use of commercial databases. The report is packed with original data in tables, charts and other formats.

I would like to order

Product name: Point of Care Coagulation Testing: World Market 2013-2023

Product link: <https://marketpublishers.com/r/P3A60943C21EN.html>

Price: US\$ 2,635.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P3A60943C21EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970